ASCT2 inhibition has been shown to reduce glutamine, leading to suppressed mammalian target of rapamycin complex 1 (mTORC1) signaling and decreased melanoma cell proliferation [61,62]. The gene discussed is SLC1A5; the disease is melanoma.